Food Allergy - Pipeline Insight, 2022

DelveInsight’s, “Food Allergy- Pipeline Insight, 2022” report provides comprehensive insights about 33+ companies and 33+ pipeline drugs in Food Allergy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
Global coverage

Food Allergy: Understanding
Food Allergy: Overview
An allergy occurs when your body’s natural defenses overreact to exposure to a particular substance, treating it as an invader and sending out chemicals to defend against it. More than 50 million Americans have an allergy of some kind. You probably know one of those people or are one yourself. Food allergies are estimated to affect 4% – 6% of children and 4% of adults. Food allergy symptoms are most common in babies and children, but they can appear at any age. You can even develop an allergy to foods you have eaten for years with no problems. The body’s immune system keeps you healthy by fighting off infections and other dangers to good health. A food allergy reaction occurs when your immune system overreacts to a food or a substance in a food, identifying it as a danger and triggering a protective response.Symptoms of a food allergy can range from mild to severe. Just because an initial reaction causes few problems doesn’t mean that all reactions will be similar; a food that triggered only mild symptoms on one occasion may cause more severe symptoms at another time. The most severe allergic reaction is anaphylaxis — a life-threatening whole-body allergic reaction that can impair your breathing, cause a dramatic drop in your blood pressure and affect your heart rate. Anaphylaxis can come on within minutes of exposure to the trigger food. It can be fatal and must be treated promptly with an injection of epinephrine (adrenaline). Once a food allergy is diagnosed, the most effective treatment is to avoid the food. The foods most associated with food allergy in children are: Milk, Eggs, Peanuts, Children may outgrow their allergic reactions to milk and to eggs. Peanut and tree nut allergies are likely to persist. The most common food allergens in adults are: Fruit and vegetable pollen (oral allergy syndrome), Peanuts and tree nuts and Fish and shellfish. A food allergy will usually cause some sort of reaction every time the trigger food is eaten. Symptoms can vary from person to person, and you may not always experience the same symptoms during every reaction. Allergic reactions to food can affect the skin, respiratory tract, gastrointestinal tract and cardiovascular system. It is impossible to predict how severe the next reaction might be, and all patients with food allergies should be carefully counseled about the risk of anaphylaxis, a potentially fatal reaction that is treated with epinephrine (adrenaline).

""Food Allergy- Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Food Allergy pipeline landscape is provided which includes the disease overview and Food Allergy treatment guidelines. The assessment part of the report embraces, in depth Food Allergy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Food Allergy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Food Allergy R&D. The therapies under development are focused on novel approaches to treat/improve Food Allergy.
Food Allergy Emerging Drugs Chapters
This segment of the Food Allergy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Food Allergy Emerging Drugs
Omalizumab: Genentech, Inc.
Omalizumab is an investigational product, which is being developed by Genetech.Omalizumab is a recombinant DNA-derived humanized IgG1 monoclonal antibody designed to selectively binds to human immunoglobulin E (IgE). This molecule is being developed in collaboration with Novartis. This drug is in Phase 3 stage of development for the treatment of food allergy.
CA002: Camallergy
CA002 is a biological drug, an investigational medicinal product employing whole peanut protein oral immunotherapy. CA002 targets best-in-class safety and efficacy by following a patient-centric treatment protocol. The CA002 formulation and advanced dosing protocol prioritise safety and efficacy as well as convenience for families and physicians. The specially-designed, pull-apart capsules are easy to use and formulated to ensure consistent delivery of characterised peanut proteins. CA002’s low-burden treatment protocol is family-friendly and efficient for physicians. Camallergy is preparing its lead product, CA002 for the treatment of peanut allergy, for Phase III trials to support regulatory approval in the US and Europe
Dupilumab: Regeneron
Regeneron and Sanofi are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes. Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. It was invented using Regeneron's proprietary VelocImmune technology. The potential uses of dupilumab is currently under clinical investigation, and the safety and efficacy in these conditions have not been fully evaluated by any regulatory authority. Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement.
INP20: InnoUp Farma
INP20 are nanoparticles with encapsulated peanut extract as a food allergen. These nanoparticles have demonstrated to be completely innocuous in animal studies when administered by oral route. INP20 aims to be a platform to develop immunotherapeutic products to treat other food allergies.The drug is currently being developed in phase1/2 for the treatment of food allergy.
PVX108: Aravax
PVX108 comprises a mixture of peptides that represent sequences from peanut allergens which are critical for recognition by peanut-specific T cells. Unlike other peanut allergy immunotherapies, PVX108 does not contain the peanut proteins (allergens) which cause severe allergic reactions. PVX108 is being developed as a simple monthly intradermal injection to induce tolerance to peanuts and reduce the risk of severe allergic reactions upon accidental exposure.
INI2004: Inimmune
Inimmune is focused on utilizing several late-stage Toll-like receptor (TLR) agonists in immuno-oncology, food allergy, and allergic rhinitis. Currently the drug INI2004,is in Pre-Clinical stage of development for the treatment of food allergies.
Further product details are provided in the report……..

Food Allergy: Therapeutic Assessment
This segment of the report provides insights about the different Food Allergy drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Food Allergy
There are approx. 33+ key companies which are developing the therapies for Food Allergy. The companies which have their Food Allergy drug candidates in the most advanced stage, i.e. phase III include, Genetech.
Phases
DelveInsight’s report covers around 33+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Food Allergy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal
Molecule Type

Products have been categorized under various Molecule types such as
Oligonucleotide
Peptide
Small molecule
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Food Allergy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Food Allergy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Food Allergy drugs.

Food Allergy Report Insights
Food Allergy Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs
Food Allergy Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Food Allergy drugs?
How many Food Allergy drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Food Allergy?
What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Food Allergy therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Food Allergy and their status?
What are the key designations that have been granted to the emerging drugs?

Key Players
Merck & Co
DBV technologies
Genentech
Camallergy
Regeneron Pharmaceuticals
InnoUp Farma
Aravax
Inimmune
Novartis Pharmaceuticals
Astrazeneca
Cour Pharmaceuticals
Siolta Therapeutics
Vedanta Biosciences
Mabylon
GI Innovation

Key Products
Viaskin Peanut
Omalizumab
CA002
Dupilumab
DBV135
INP20
PVX108
STMC-103H
Ligelizumab
INI2004
Acalabrutinib
AR201
CNP-201
ADP101
VE 416